News

The chief executive officer of clinical stage biopharmaceutical company Corbus Pharmaceuticals Holdings, Yuval Cohen, Ph.D., is presenting an update on the company’s research, as well as revision of previous clinical developments regarding Corbus’s lead product candidate, Resunab, at the Leerink Partners Rare Disease Roundtable. The product candidate is being studied by the drug…

The Scleroderma Foundation announced that their national Board of Directors is merging the Southern California Chapter with the Greater San Diego Chapter, in order to increase the efficiency of their support and education programs. The merger was proposed by the chapters themselves and approved by the board, and the…

Having previously experimented with the use of Viagra (Sildenafil) as a possible therapy for Pulmonary arterial hypertension (PAH), researchers have now evaluated the use of the drug in treating Systemic Sclerosis (SSc) in patients. SSc or scleroderma, is a chronic connective tissue disease characterized by hardening of the skin. The…

Scleroderma is a rare, chronic rheumatic disease, combined forms of which, including localized, systemic, and related conditions, affecting an estimated 300,000 Americans, primarily females who are 30 to 50 years old at onset. The overall occurrence of Scleroderma is 1 per 1,000 (.1% of the 310 million U.S. population)…

Scleroderma patients should be screened every year for pulmonary hypertension, even if they are recently diagnosed and have no respiratory symptoms, according to one of the foremost research authorities on the disease. Scleroderma, or systemic sclerosis, is a chronic connective tissue disease generally classified as one of the autoimmune rheumatic…

Protagen AG, which specializes in diagnostic medical devices for autoimmune diseases, has launched its first ELISA research use test kit, developed for Systemic Sclerosis (SSc), the ADx®SSc Multilisa®. The diagnostic test was developed by Protagen with the purpose of combining both the identification of novel disease markers and two standard…

Active Biotech, a Sweden-based biopharmaceutical company that is developing therapies for autoimmune diseases, inflammatory diseases, and cancers, recently announced that it is partnering with Teva Pharmaceutical Industries Ltd. to develop a new, experimental drug for treating Huntington’s disease. The two companies will work together to launch a new phase 2 clinical trial in…

Nonsense mutation Duchenne muscular dystrophy (nmDMD) patients living in the European Union may soon experience relief from their condition due to the European Commission granting PTC Therapeutics, Inc. conditional marketing for Translarna™ (ataluren). PTC Therapeutics may now market Translarna in the 28 Member States of the…